2025 ESMO Prostate Cancer Highlights - Takeaways - MDSpire
Advertisement
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025
The ESMO 2025 updates highlight the role of enzalutamide in high-risk localized prostate cancer and its impact on metastasis-free survival.
2
The NZRAD trial found no overall survival benefit from adding enzalutamide to ADT and radiation for most localized prostate cancer patients.
3
Patients with node-positive disease showed improved metastasis-free survival when treated with enzalutamide, suggesting a tailored approach is necessary.
4
The Embark study demonstrated that enzalutamide plus ADT significantly improves overall survival in high-risk biochemical relapse prostate cancer.
5
Adverse events were higher in enzalutamide treatment arms, emphasizing the need for careful patient selection and monitoring.
